Repligen Corporation (RGEN) 2026 KeyBanc Capital Markets Healthcare Virtual Forum March 18, 2026 2:15 PM EDT
Company Participants
Olivier Loeillot – President, CEO & Director
Jason Garland – CFO & Chief Compliance Officer
Conference Call Participants
Paul Knight – KeyBanc Capital Markets Inc., Research Division
Anna Snopkowski – KeyBanc Capital Markets Inc., Research Division
Presentation
Paul Knight
KeyBanc Capital Markets Inc., Research Division
This is Paul Knight, life science analyst at Repligen. And with us, we have Jacob Johnson, Head of Investor Relations; Jason, Chief Financial Officer; Olivier, CEO. We all very familiar with Repligen management. In fact, when I first met them at $3 a share, it was in the building I’m sitting in right now at 1301 Sixth Avenue.
Question-and-Answer Session
Paul Knight
KeyBanc Capital Markets Inc., Research Division
So they’ve come a long way. And Olivier, you’ve been there — you’ve not been there forever. What are your impressions now as the CEO a bit of how Repligen is positioned and how this market feels to you?
Olivier Loeillot
President, CEO & Director
Yes. No, that’s a great question, Paul. I mean I’ve been here for about 2.5 years now, CEO of the company for 1.5 years. I mean, I’m obviously more excited than ever. I mean we have a very unique and very broad offering at the same time. And with our very intense commercial strategy, I mean, we’ve been very successful over the last couple of years to really get more and more closer to those big companies and getting them understanding we have a very broad portfolio of products.
You know very well, like innovation has always been really at the core of our DNA, and we’re still doubling down on innovation as well because we really want to make sure we are helping our customers to
Read the full article here